Keyphrases
5-HT2A Receptor
9%
Adverse Events
9%
Alzheimer's Disease
45%
Atrial Fibrillation
8%
Bipolar Disorder
11%
Calcitonin Gene-related Peptide
27%
Cerebral Blood Flow
23%
Cerebrospinal Fluid
30%
Chronic Migraine
10%
Clinical Outcomes
10%
Clinical Practice
10%
Clinical Trials
12%
Cluster Headache
18%
Cognitive Function
10%
Cognitive Impairment
13%
Comorbidity
12%
Confidence Interval
33%
Copenhagen
11%
COVID-19
10%
Dementia
32%
Dementia Diagnosis
8%
Denmark
49%
Diagnostic Criteria
9%
Disability
14%
Disease Activity
8%
Disease-modifying Therapy
10%
Effectiveness Research
9%
Electroencephalography
9%
Epilepsy
14%
Europe
17%
Frontotemporal Dementia
12%
Functional Magnetic Resonance Imaging
15%
Functional Outcome
8%
Genome-wide Association Study
9%
Hazard Ratio
10%
Headache
56%
Healthy Controls
30%
Healthy Individuals
13%
Healthy Volunteers
18%
High Risk
8%
Hippocampus
9%
Huntington's Disease
10%
Idiopathic Intracranial Hypertension
10%
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD)
12%
Intensive Care Unit
13%
Intracranial Pressure
17%
Ischemic Stroke
13%
Magnetic Resonance Imaging
20%
Major Depressive Disorder
12%
McArdle Disease
10%
Medication Overuse Headache
11%
Memory Clinic
9%
Meningioma
9%
Meta-analysis
23%
Migraine
75%
Migraine Attack
18%
Migraine Patients
10%
Migraine Treatment
14%
Migraine without Aura (MWoA)
23%
Mild Cognitive Impairment
11%
Multiple Sclerosis
100%
Multiple Sclerosis Treatment
18%
Narcolepsy
15%
National Cohort Study
13%
Neurodegenerative Diseases
11%
Neurotrauma
10%
Non-associated
9%
Odds Ratio
15%
Older Adults
8%
Optic Neuritis
9%
Parkinson's Disease
12%
Pathophysiology
11%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
8%
Placebo
34%
Placebo-controlled
13%
Polysomnography
10%
Population-based Study
8%
Positron Emission Tomography
20%
Progressive multiple Sclerosis
10%
Quality of Life
16%
Radioligand
8%
Randomized Clinical Trial
16%
Randomized Controlled Trial
23%
Randomized Double-blind
8%
Randomized Placebo-controlled Trial
10%
Randomized Trial
9%
Receptor Binding
12%
Regional Cerebral Blood Flow (rCBF)
8%
Relapsing-remitting multiple Sclerosis
19%
Risk Factors
17%
Serotonin 2A Receptor (5-HT2AR)
11%
Serotonin Transporter
8%
Severe Traumatic Brain Injury (sTBI)
11%
Single-photon Emission Computed Tomography (SPECT)
10%
Spinal Cord Injury
43%
Subarachnoid Hemorrhage
14%
Sumatriptan
8%
Systematic Meta-analysis
16%
Tension-type Headache
13%
Traumatic Brain Injury
29%
Medicine and Dentistry
Acquired Brain Injury
5%
Adverse Event
10%
Alzheimer's Disease
16%
Analgesia
5%
Anodyne
5%
Apoplexy
34%
Artery
8%
Atrial Fibrillation
7%
Auras
6%
Biological Marker
18%
Blood Pressure
6%
Brain Blood Flow
15%
Brain Injury
10%
Brain Ischemia
14%
Brain Tumor
5%
Calcitonin Gene Related Peptide
12%
Case-Control Study
7%
Cerebral Hemorrhage
9%
Cerebrospinal Fluid
12%
Clinical Trial
11%
Clinician
6%
Cluster Headache
9%
Cognition
5%
Cohort Analysis
23%
Cohort Effect
5%
Computer Assisted Tomography
6%
COVID-19
9%
Cross Sectional Study
6%
Diagnosis
28%
Disease
43%
Disorders of Consciousness
5%
Drug Therapy
14%
Epileptic Seizure
8%
Erenumab
5%
Exercise
6%
Functional Magnetic Resonance Imaging
5%
Ganglioglioma
8%
Glioblastoma
6%
Global Disease Burden
6%
Glycogen Storage Disease Type V
9%
Hazard Ratio
6%
Headache
44%
Headache and Facial Pain
5%
Health Care
6%
Health Care Cost
7%
Heart Arrest
6%
Hydrocephalus
5%
Hypoxia
5%
Idiopathic Intracranial Hypertension
7%
Infection
8%
Infusion
8%
Injury
19%
Intensive Care Unit
13%
Intracranial Pressure
10%
Magnetic Resonance Imaging
33%
Malignant Neoplasm
7%
Medication Overuse Headache
7%
Meningioma
7%
Meta-Analysis
16%
Migraine
56%
Migraine with Aura
7%
Migraine without Aura
5%
Multiple Sclerosis
42%
Muscle Strength
6%
Myopathy
8%
Neoplasm
13%
Nervous System Injury
7%
Neurologic Disease
7%
Neurology
5%
Observational Study
10%
Obstructive Sleep Apnea
5%
Odds Ratio
8%
Opiate
8%
Pathophysiology
8%
Pediatrics
9%
Placebo
25%
Positron Emission Tomography
9%
Prevalence
16%
Prophylaxis
6%
Prospective Study
5%
Quality of Life
14%
Randomized Clinical Trial
12%
Randomized Controlled Trial
16%
Receptor
5%
Rehabilitation Engineering
14%
Skeletal Muscle
5%
Spinal Cord Injury
32%
Subarachnoid Hemorrhage
8%
Surgery
9%
Symptom
34%
Symptomatic Treatment
5%
Systematic Review
34%
Tension Headache
10%
Transformed Migraine
5%
Transient Ischemic Attack
5%
Traumatic Brain Injury
26%
Trigeminal Neuralgia
5%
Volunteer
8%